Results 171 to 180 of about 5,634,404 (299)

From a microscopic inertial active matter model to the Schrödinger equation. [PDF]

Nat Commun, 2023
Te Vrugt M, Frohoff-Hülsmann T, Heifetz E, Thiele U, Wittkowski R.   +4 more
europepmc   +1 more source

Targeting transcription factors associated with hemoglobinopathies: Lessons from successful interventions and implications for cancer

Molecular Oncology, EarlyView.
This review summarizes the transcription factors, repressive chromatin‐modifying complexes, and epigenetic mechanisms that control fetal hemoglobin repression. Notably, many regulators of γ‐globin silencing also function in transcriptional and epigenetic networks that drive cancer, highlighting opportunities to translate advances in hemoglobinopathy ...
Meigen Yu, Puspa Das, Xing Zhang, Xiaodong Cheng   +3 more
wiley   +1 more source

View taken from top of Mount Sir Thomas - looking north east [picture] /

, 1891
Also available in an electronic version via the Internet at: http://nla.gov.au/nla.pic-an6647833 ...
Elliott, Frederick, active 1855-1897.
core  

Emergence of precursor instabilities in geo-processes: Insights from dense active matter. [PDF]

Heliyon, 2023
Regenauer-Lieb K, Hu M.
europepmc   +1 more source

CEACAM1 participation in breast cancer progression

Molecular Oncology, EarlyView.
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin, Irina Kube‐Golovin, Anatolii Romaniuk, Gunther Wennemuth   +3 more
wiley   +1 more source

Geometrical control of interface patterning underlies active matter invasion. [PDF]

Proc Natl Acad Sci U S A, 2023
Xu H, Nejad MR, Yeomans JM, Wu Y.
europepmc   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

Camp No. 15. - view of range, looking south [picture] /

, 1891
Also available in an electronic version via the Internet at: http://nla.gov.au/nla.pic-an6647833 ...
Elliott, Frederick, active 1855-1897.
core  

Fabrication of microcompartments with controlled size and shape for encapsulating active matter [PDF]

Front Cell Dev Biol
Vianay B, Guérin C, Gressin L, Orhant-Prioux M, Blanchoin L, Théry M, Colin A.   +6 more
europepmc   +2 more sources

PANoptosis in the pathogenesis of myelodysplastic syndromes

Molecular Oncology, EarlyView.
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla, Jyoti Lamichhane, Cameron Lewis, Peter Breslin, Jiwang Zhang   +4 more
wiley   +1 more source